Can B Corp. (CANB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Can B Corp. (CANB) with AI Score 38/100 (Weak). Can B Corp. is a U. S. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Can B Corp. (CANB) Healthcare & Pipeline Overview
Can B Corp. focuses on the development, manufacturing, and sale of CBD-based products in the United States, offering a diverse range of hemp-derived products through its website, vending machines, and medical professionals, positioning itself within the competitive and evolving CBD market.
Investment Thesis
Can B Corp. presents a speculative investment opportunity within the high-growth CBD market. Key value drivers include the expansion of its product line and distribution channels. Growth catalysts include increasing consumer awareness and acceptance of CBD products, as well as potential regulatory changes that could broaden market access. However, the company faces significant risks, including intense competition, evolving regulations, and the need for substantial capital to scale operations. With a market capitalization of $0.00B and a negative P/E ratio of -0.10, the company's financial performance requires close monitoring. Investors should carefully consider the risks and uncertainties associated with this OTC-traded stock.
Based on FMP financials and quantitative analysis
Key Highlights
- Can B Corp. operates in the cannabidiol (CBD) market, which is projected to reach billions of dollars in the coming years.
- The company offers a diversified product line including oils, creams, moisturizers, and concentrates under brands like Canbiola and Nu Wellness.
- Can B Corp. distributes its products through its website, vending machines, and medical professionals.
- The company rebranded from Canbiola Inc. to Can B Corp. in February 2020, signaling a strategic focus on the CBD market.
- Can B Corp. has a beta of 0.85, indicating lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Established brand names (Canbiola, Nu Wellness, etc.)
- Diverse product line of CBD products
- Multiple distribution channels (website, vending machines, medical professionals)
- Focus on hemp-derived CBD products
Weaknesses
- Limited market capitalization ($0.00B)
- Negative P/E ratio (-0.10)
- OTC listing indicates higher risk
- Small number of employees (12)
Catalysts
- Upcoming: Potential regulatory changes in the CBD market could expand market access and increase demand for Can B Corp.'s products.
- Ongoing: Increasing consumer awareness and acceptance of CBD products is driving market growth and creating opportunities for Can B Corp.
- Ongoing: Expansion of distribution channels through partnerships with retailers and healthcare providers could boost sales and market share.
Risks
- Potential: Intense competition in the CBD market could erode Can B Corp.'s market share and profitability.
- Potential: Evolving regulations and regulatory uncertainty could create compliance challenges and increase operating costs.
- Potential: Fluctuations in hemp prices could impact Can B Corp.'s gross margins.
- Ongoing: The company's OTC listing indicates higher risk and potential for price volatility.
- Ongoing: Limited financial disclosure increases the risk for investors.
Growth Opportunities
- Expansion of Product Line: Can B Corp. can capitalize on the growing CBD market by expanding its product line to include new and innovative formulations, such as CBD-infused beverages, edibles, and pet products. The global CBD market is projected to reach $55.79 billion by 2028, offering significant growth potential. Timeline: Within the next 2-3 years, Can B Corp. can introduce new product lines to cater to evolving consumer preferences.
- Strategic Partnerships: Forming strategic partnerships with established retailers, distributors, and healthcare providers can significantly expand Can B Corp.'s market reach and brand visibility. Collaborations with major retail chains or online marketplaces can provide access to a wider customer base. Timeline: Can B Corp. should actively pursue partnership opportunities within the next 12-18 months.
- Geographic Expansion: Expanding into new geographic markets, both domestically and internationally, represents a significant growth opportunity for Can B Corp. The European CBD market, for example, is experiencing rapid growth and offers attractive opportunities for expansion. Timeline: Can B Corp. should conduct market research and develop a phased expansion strategy over the next 3-5 years.
- Focus on Research and Development: Investing in research and development to develop proprietary CBD formulations and delivery methods can provide a competitive advantage and attract strategic partnerships. Clinical studies and scientific validation can enhance the credibility and market acceptance of Can B Corp.'s products. Timeline: Ongoing investment in R&D is crucial for long-term growth and differentiation.
- Direct-to-Consumer (DTC) Sales: Strengthening its direct-to-consumer (DTC) sales channels through its website and online marketing efforts can improve Can B Corp.'s profit margins and customer relationships. Investing in e-commerce infrastructure and digital marketing campaigns can drive online sales growth. Timeline: Can B Corp. should prioritize enhancing its DTC capabilities within the next 6-12 months.
Opportunities
- Expanding into new geographic markets
- Developing new and innovative CBD products
- Forming strategic partnerships with retailers and distributors
- Increasing consumer awareness and acceptance of CBD products
Threats
- Intense competition in the CBD market
- Evolving regulations and regulatory uncertainty
- Fluctuations in hemp prices
- Potential for negative publicity or product recalls
Competitive Advantages
- Brand recognition through its Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil brands.
- Distribution network including website, vending machines, and medical professionals.
- Proprietary formulations and product development capabilities.
About CANB
Can B Corp., formerly Canbiola Inc., was founded in 2005 and is headquartered in Hicksville, New York. The company operates within the rapidly evolving cannabidiol (CBD) market, focusing on the development, manufacture, and sale of CBD-based products. These products are derived from hemp and include a variety of formulations such as oils, creams, moisturizers, isolates, gel caps, spa products, concentrates, and lifestyle products. Can B Corp. distributes its products through multiple channels, including its website, vending machines, and partnerships with medical professionals. The company markets its offerings under several brand names, including Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil, targeting a broad consumer base interested in CBD for wellness and therapeutic purposes. The rebranding from Canbiola Inc. to Can B Corp. in February 2020 reflects the company's strategic shift and focus on the CBD market.
What They Do
- Develops cannabidiol (CBD) based products.
- Manufactures CBD products derived from hemp.
- Sells CBD products in the United States.
- Offers CBD oils, creams, moisturizers, and other formulations.
- Distributes products through its website, vending machines, and medical professionals.
- Markets products under the Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil brands.
Business Model
- Develops and manufactures CBD products from hemp.
- Sells products directly to consumers through its website and vending machines.
- Distributes products through partnerships with medical professionals.
Industry Context
Can B Corp. operates within the rapidly expanding CBD market, driven by increasing consumer interest in natural health and wellness products. The market is characterized by intense competition, evolving regulations, and a fragmented landscape of producers and retailers. Companies like Can B Corp. are vying for market share by differentiating themselves through product innovation, branding, and distribution strategies. The industry faces ongoing challenges related to regulatory uncertainty and the need for standardized quality control measures. The company competes with ACNNF (Acreage Holdings), CBDNF (Charlotte's Web Holdings), CIMVF (Columbia Care Inc.), ETRGF (Green Thumb Industries), and IWINF (iAnthus Capital Holdings).
Key Customers
- Consumers seeking CBD products for wellness and therapeutic purposes.
- Medical professionals who recommend or sell CBD products to their patients.
- Retail customers who purchase CBD products through vending machines.
Financials
Chart & Info
Can B Corp. (CANB) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Sep 30, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CANB.
Price Targets
Wall Street price target analysis for CANB.
MoonshotScore
What does this score mean?
The MoonshotScore rates CANB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Marco Alfonsi
CEO
Marco Alfonsi serves as the CEO of Can B Corp. His background and prior experience are not detailed in the provided information. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. He manages a team of 12 employees and is focused on growing Can B Corp.'s presence in the CBD market.
Track Record: Due to limited information, Marco Alfonsi's specific achievements and strategic decisions at Can B Corp. cannot be fully assessed. His leadership is focused on navigating the competitive CBD market and expanding the company's product offerings and distribution channels.
CANB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Can B Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to stocks listed on national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other listing.
- Potential for low trading volume and wide bid-ask spreads.
- Higher risk of price manipulation and fraud.
- Limited regulatory oversight compared to major exchanges.
- Uncertainty regarding the company's long-term viability.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive position and market share.
- Evaluate the company's regulatory compliance and risk management practices.
- Monitor the company's trading volume and price volatility.
- Consult with a qualified financial advisor before investing.
- Confirm the legitimacy of the company's business operations.
- Established presence in the CBD market since 2005.
- Multiple brand names (Canbiola, Nu Wellness, etc.)
- Distribution through website, vending machines, and medical professionals.
Common Questions About CANB
What does Can B Corp. do?
Can B Corp. develops, manufactures, and sells cannabidiol (CBD) based products in the United States. The company provides CBD products derived from hemp, including oils, creams, moisturizers, isolate, gel caps, spa products, concentrates, and life style products through its Website and vending machines, and other medical professionals. It offers its products under the Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil brands, catering to consumers seeking wellness and therapeutic benefits from CBD.
What do analysts say about CANB stock?
As of 2026-03-15, there is no available analyst coverage or consensus on Can B Corp. (CANB) stock. The company's market capitalization is $0.00B, and it has a negative P/E ratio of -0.10. Given its OTC listing and limited financial information, investors should conduct thorough due diligence and consider the risks associated with this stock. The company's growth potential is tied to the expansion of the CBD market and its ability to differentiate itself from competitors.
What are the main risks for CANB?
The main risks for Can B Corp. include intense competition in the CBD market, evolving regulations and regulatory uncertainty, fluctuations in hemp prices, and the company's OTC listing, which indicates higher risk and potential for price volatility. Additionally, the company's limited financial disclosure increases the risk for investors, as it is unclear what financial reports are publicly available or how frequently the company provides updates on its performance. Investors should carefully consider these risks before investing in CANB.
What are the key factors to evaluate for CANB?
Can B Corp. (CANB) currently holds an AI score of 38/100, indicating low score. Key strength: Established brand names (Canbiola, Nu Wellness, etc.). Primary risk to monitor: Potential: Intense competition in the CBD market could erode Can B Corp.'s market share and profitability.. This is not financial advice.
How frequently does CANB data refresh on this page?
CANB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CANB's recent stock price performance?
Recent price movement in Can B Corp. (CANB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established brand names (Canbiola, Nu Wellness, etc.). Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CANB overvalued or undervalued right now?
Determining whether Can B Corp. (CANB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CANB?
Before investing in Can B Corp. (CANB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Can B Corp.'s financials and operations.
- OTC listing indicates higher risk and potential for price volatility.
- Analyst coverage is not available for this stock.